

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroTech Medical (Hangzhou) Co., Ltd.

微泰醫療器械（杭州）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2235)

VOLUNTARY ANNOUNCEMENT OVERSEAS APPROVAL OF THE COMPANY'S CONTINUOUS GLUCOSE MONITORING SYSTEM

This announcement is published by MicroTech Medical (Hangzhou) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, for the purpose of keeping the shareholders and potential investors of the Company informed of the latest development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of the Company is pleased to announce that Our LinX Continuous Glucose Monitoring System has recently received marketing approval in South Korea for continuous glucose monitoring in adults.

As a key market in East Asia, South Korea features comprehensive reimbursement coverage, strong patient affordability and substantial market potential. According to the 2025 IDF Diabetes Atlas published by the International Diabetes Federation (“**IDF**”), in 2024 there are approximately 5 million people aged 20–79 living with diabetes in South Korea, representing an adult a prevalence rate of 9.6%. Total diabetes-related healthcare expenditure in South Korea amounted to approximately US\$11.63 billion for 2024, with average annual diabetes-related healthcare spending of US\$2,312.1 per patient, placing the country's per capita healthcare expenditure among the highest in Asia.

The approval of the LinX Continuous Glucose Monitoring System for marketing in South Korea represents a significant milestone in expanding the Company's market access across East Asia and further strengthens the Group's commercial channel competitiveness in established Asian markets. This approval also lays a solid foundation for the scaling of the Group's international business and the growth of its overseas revenue. Going forward, the Company will continue to focus on the global development of diabetes monitoring, treatment and management solutions, and persistently drive ongoing innovation in related technologies and products.

The Company reminds the investors that the production, sales and the resulting income of the above-mentioned product are affected by many factors such as market changes. Shareholders and potential investors of the Company are requested to exercise caution when dealing with the shares of the Company.

By order of the Board
MicroTech Medical (Hangzhou) Co., Ltd.
Zheng Pan
Chairman of the Board

Hangzhou, the PRC, July 14, 2026

As at the date of this announcement, the executive Directors are Dr. Zheng Pan, Dr. Yu Fei, Dr. Shi Yonghui and Ms. Liu Xiu; the non-executive Directors are Mr. Mao Shuo and Ms. Gao Yun; and the independent non-executive Directors are Dr. Li Lihua, Ms. Wang Chunfeng, Mr. Ho Kin Cheong Kelvin and Dr. Cheng Hua.